Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort

Francesco Nicoli, Mkunde Chachage, Petra Clowes, Asli Bauer, Dickens Kowour, Barbara Ensoli, Aurelio Cafaro, Leonard Maboko, Michael Hoelscher, Riccardo Gavioli, Elmar Saathoff & Christof Geldmacher

The presence of IgG and IgM against Tat, an HIV protein important for viral replication and immune dysfunction, is associated with slow disease progression in clade B HIV-infected individuals. However, although Tat activities strictly depend on the viral clade, our knowledge about the importance of anti-Tat antibodies in non-clade B HIV infection is poor. The objective of this study was to investigate the association of different anti-Tat antibody isotypes with disease progression in non-clade B HIV-infected subjects and to study the relationship between anti-Tat humoral responses and immunological abnormalities.

Published at:  2016-07-22

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Cecilia Rademeyer,Bette Korber,Michael S. Seaman,Elena E. Giorgi,Ruwayhida Thebus,Alexander Robles,Daniel J. Sheward,Kshitij Wagh,Jetta Garrity,Brittany R. Carey,Hongmei Gao,Kelli M. Greene,Haili Tang,Gama P. Bandawe,Jinny C. Marais,Thabo E. Diphoko,Peter Hraber,Nancy Tumba,Penny L. Moore,Glenda E. Gray,James Kublin,M. Juliana McElrath,Marion Vermeulen,Keren Middelkoop,Linda-Gail Bekker,Michael Hoelscher,Leonard Maboko,Joseph Makhema,Merlin L. Robb,Salim Abdool Karim,Quarraisha Abdool Karim,Jerome H. Kim,Beatrice H. Hahn,Feng Gao,Ronald Swanstrom,Lynn Morris,David C. Montefiori,Carolyn Williamson

The development of biomedical interventions to reduce acquisition of HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high HIV-1 envelope diversity. Two large prophylactic trials in high incidence, clade C epidemic regions in southern Africa are imminent; passive administration of the monoclonal antibody VRC01, and active immunization with a clade C modified RV144-like vaccines. We have created a large representative panel of C clade viruses to enable assessment of antibody responses to vaccines and natural infection in Southern Africa, and we investigated the genotypic............

Published at:  2016-07-19

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

Agricola Joachim ,Asli Bauer ,Sarah Joseph,Christof Geldmacher,Patricia J. Munseri,Said Aboud,Marco Missanga,Philipp Mann,Britta Wahren,Guido Ferrari,Victoria R. Polonis,Merlin L. Robb,Jonathan Weber,Roger Tatoud,Leonard Maboko,Michael Hoelscher,Eligius F. Lyamuya,Gunnel Biberfeld,Eric Sandström,Arne Kroidl,Muhammad Bakari,Charlotta Nilsson,Sheena McCormack

A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously given three immunizations with HIV-DNA followed by two immunizations with recombinant modified vaccinia virus Ankara (HIV-MVA).

Published at:  2016-05-18

Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania

Inge Kroidl ,Elmar Saathof ,Lucas Maganga,Petra Clowes,Leonard Maboko,Achim Hoerauf,Williams H. Makunde,Antelmo Haule,Prisca Mviombo,Bettina Pitter,Neema Mgeni,Joseph Mabuye,Dickens Kowuor,Upendo Mwingira,Mwelecele N. Malecela,Thomas Löscher,Michael Hoelscher

Annual mass treatment with ivermectin and albendazole is used to treat lymphatic filariasis in many African countries, including Tanzania. In areas where both diseases occur, it is unclear whether HIV co-infection reduces treatment success.

Published at:  2016-04-12

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania

Inge Kroidl, Petra Clowes, Klaus Reither, Bariki Mtafya, Gabriel Rojas-Ponce, Elias N. Ntinginya, Mariam Kalomo, Lilian T. Minja, Dickens Kowuor, Elmar Saathoff, Arne Kroidl, Norbert Heinrich, Leonard Maboko, Matthew Bates, Justin O'Grady, Alimuddin Zumla, Michael Hoelscher, Andrea Rachow

We evaluated the diagnostic performance of two tests based on the release of lipoarabinomannan (LAM) into the urine, the MTB-LAM-ELISA assay and the Determine TB-LAM-strip assay, in children with suspected tuberculosis (TB) in a high TB/HIV-prevalence setting. In a prospective study, 132 children with suspected active TB were assigned to diagnostic subgroups. Urine samples were subjected to testing by both assays to ascertain sensitivity and specificity. Host factors associated with positive LAM results were investigated and LAM excretion ..........

Published at:  2015-08-31

Towards host-directed therapies for tuberculosis

Alimuddin Zumla, Jeremiah Chakaya, Michael Hoelscher, Francine Ntoumi, Roxana Rustomjee, Cristina Vilaplana, Dorothy Yeboah-Manu, Voahangy Rasolofo, Paula Munderi, Nalini Singh, Eleni Aklillu, Nesri Padayatchi, Eusebio Macete, Nathan Kapata, Modest Mulenga, Gibson Kibiki, Sayoki Mfinanga, Thomas Nyirenda, Leonard Maboko, Alberto Garcia-Basteiro, Niaina Rakotosamimanana, Matthew Bates, Peter Mwaba, Klaus Reither, Sebastien Gagneux, Sarah Edwards, Elirehema Mfinanga, Salim Abdulla, Pere-Joan Cardona, James B.W. Russell, Vanya Gant, Mahdad Noursadeghi, Paul Elkington, Maryline Bonnet, Clara Menendez, Tandakha N. Dieye, Bassirou Diarra, Almoustapha Maiga, Abraham Aseffa, Shreemanta Parida, Christian Wejse, Eskild Petersen, Pontiano Kaleebu, Matt Oliver, Gill Craig, Tumena Corrah, Leopold Tientcheu, Martin Antonio, Martin Rao, Timothy D. McHugh, Aziz Sheikh, Giuseppe Ippolito, Gita Ramjee, Stefan H. E. Kaufmann, Gavin Churchyard, Andrie Steyn, Martin Grobusch, Ian Sanne, Neil Martinson, Rajhmun Madansein, Robert J. Wilkinson, Bongani Mayosi, Marco Schito, Robert S. Wallis & Markus Maeurer

The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.

Published at:  2015-07-17

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

Authors: Lindsay Wieczorek, Shelly J. Krebs, Vaniambadi Kalyanaraman, Stephen Whitney, Sodsai Tovanabutra, Carlos G. Moscoso, Eric Sanders-Buell, Constance Williams, Bonnie Slike, Sebastian Molnar, Vincent Dussupt, S. Munir Alam, Agnes-Laurence Chenine, Tina Tong, Edgar L. Hill, Hua-Xin Liao, Michael Hoelscher, Leonard Maboko, Susan Zolla-Pazner, Barton F. Haynes, Michael Pensiero, Francine McCutchan, Shawyon Malek-Salehi, R. Holland Cheng, Merlin L. Robb, Thomas VanCott, Nelson L. Michael, Mary A. Marovich, Carl R. Alving, Gary R. Matyas, Mangala Rao, Victoria R. Polonis

Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was.............

Published at:  2015-07-08

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Authors: Rodney Dawson MD a, Andreas H Diacon MD b e, Dr Daniel Everitt MD f, Christo van Niekerk MD g, Peter R Donald MD c, Divan A Burger MCom h i, Robert Schall PhD h i, Melvin Spigelman MD f, Almari Conradie MPh g, Kathleen Eisenach PhD j, Amour Venter NatDipMicr d k, Prudence Ive FCP[SA] l, Liesl Page-Shipp MBBCh n, Ebrahim Variava MD m, Klaus Reither MD o p, Nyanda E Ntinginya MD q, Alexander Pym MD r, Florian von Groote-Bidlingmaier MD e, Carl M Mendel MD f

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks of treatment.

Published at:  2015-05-08

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial

Patricia. J. Munseri ,Arne Kroidl ,Charlotta Nilsson,Agricola Joachim,Christof Geldmacher,Philipp Mann,Candida Moshiro,Said Aboud,Eligius Lyamuya,Leonard Maboko,Marco Missanga,Bahati Kaluwa,Sayoki Mfinanga,Lilly Podola,Asli Bauer,Karina Godoy-Ramirez,Mary Marovich,Bernard Moss,Michael Hoelscher,Frances Gotch,Wolfgang Stöhr,Richard Stout,Sheena McCormack,Britta Wahren,Fred Mhalu,Merlin L. Robb,Gunnel Biberfeld,Eric Sandström,Muhammad Bakari

Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explores whether HIV-DNA priming can be simplified by reducing the number of DNA injections and administration of combined versus separated plasmid pools.

Published at:  2015-04-15

Publication Archive

  • 2023 (6 publications)
  • 2022 (12 publications)
  • 2021 (5 publications)
  • 2020 (2 publications)
  • 2019 (2 publications)
  • 2018 (7 publications)
  • 2017 (8 publications)
  • 2016 (7 publications)
  • 2015 (7 publications)
  • 2014 (5 publications)
  • 2013 (5 publications)
  • 2012 (3 publications)
  • 2011 (4 publications)
  • 2010 (5 publications)
  • 2009 (5 publications)
  • 2008 (3 publications)
  • 2007 (3 publications)
  • 2006 (2 publications)
  • 2005 (2 publications)
  • 2004 (2 publications)
  • 2001 (1 publications)